LIFEVANTAGE CORP Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
LIFEVANTAGE CORP (LFVN) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$699.00 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-27.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-27
- LIFEVANTAGE CORP other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$142.00K, a 138.17% decline year-over-year.
- LIFEVANTAGE CORP other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$118.00K, a 145.74% decline year-over-year.
- LIFEVANTAGE CORP other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was -$259.00K.
- LIFEVANTAGE CORP other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was -$180.00K, a 122.76% decline year-over-year.
- LIFEVANTAGE CORP other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2026 was -$699.00K, a 194.33% decline from fiscal 2025.
- LIFEVANTAGE CORP other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $741.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$142.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-27 | -$260.00K derived: sum of 2 quarters · filed 2026-08-27 | -$519.00K derived: sum of 3 quarters · filed 2026-08-27 | -$699.00K 10-K · filed 2026-08-27 |
| 2026-03-31 | -$118.00K 10-Q · filed 2026-05-06 | -$377.00K derived: sum of 2 quarters · filed 2026-05-06 | -$557.00K 10-Q · filed 2026-05-06 | -$185.00K derived: sum of 4 quarters · filed 2026-08-27 |
| 2025-12-31 | -$259.00K 10-Q · filed 2026-02-04 | -$439.00K 10-Q · filed 2026-02-04 | -$67.00K derived: sum of 3 quarters · filed 2026-08-27 | $191.00K derived: sum of 4 quarters · filed 2026-08-27 |
| 2025-09-30 | -$180.00K 10-Q · filed 2025-11-04 | $192.00K derived: sum of 2 quarters · filed 2026-08-27 | $450.00K derived: sum of 3 quarters · filed 2026-08-27 | -$230.00K derived: sum of 4 quarters · filed 2026-08-27 |
| 2025-06-30 | $372.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-27 | $630.00K derived: sum of 2 quarters · filed 2026-08-27 | -$50.00K derived: sum of 3 quarters · filed 2026-08-27 | $741.00K 10-K · filed 2026-08-27 |
| 2025-03-31 | $258.00K 10-Q · filed 2026-05-06 | -$422.00K derived: sum of 2 quarters · filed 2026-05-06 | $369.00K 10-Q · filed 2026-05-06 | |
| 2024-12-31 | -$680.00K 10-Q · filed 2026-02-04 | $111.00K 10-Q · filed 2026-02-04 | ||
| 2024-09-30 | $791.00K 10-Q · filed 2025-11-04 | |||
| 2024-03-31 | -$529.00K 10-Q · filed 2025-05-06 | -$66.00K derived: sum of 2 quarters · filed 2025-05-06 | -$360.00K 10-Q · filed 2025-05-06 | |
| 2023-12-31 | $463.00K 10-Q · filed 2025-02-05 | $169.00K 10-Q · filed 2025-02-05 | ||
| 2023-09-30 | -$294.00K 10-Q · filed 2024-10-29 | |||
| 2023-03-31 | $14.00K 10-Q · filed 2024-05-02 | $654.00K derived: sum of 2 quarters · filed 2024-05-02 | $144.00K 10-Q · filed 2024-05-02 | |
| 2022-12-31 | $640.00K 10-Q · filed 2024-01-30 | $130.00K 10-Q · filed 2024-01-30 | ||
| 2022-09-30 | -$510.00K 10-Q · filed 2023-11-09 | |||
| 2022-03-31 | -$290.00K 10-Q · filed 2023-05-04 | -$469.00K derived: sum of 2 quarters · filed 2023-05-04 | -$604.00K 10-Q · filed 2023-05-04 | |
| 2021-12-31 | -$179.00K 10-Q · filed 2023-02-02 | -$314.00K 10-Q · filed 2023-02-02 | ||
| 2021-09-30 | -$135.00K 10-Q · filed 2022-11-02 | |||
| 2021-03-31 | -$443.00K 10-Q · filed 2022-05-03 | -$199.00K derived: sum of 2 quarters · filed 2022-05-03 | -$39.00K 10-Q · filed 2022-05-03 | |
| 2020-12-31 | $244.00K 10-Q · filed 2022-02-01 | $404.00K 10-Q · filed 2022-02-01 | ||
| 2020-09-30 | $160.00K 10-Q · filed 2021-11-04 | |||
| 2020-03-31 | $0.00 10-Q · filed 2021-04-29 | -$14.00K derived: sum of 2 quarters · filed 2021-04-29 | -$30.00K 10-Q · filed 2021-04-29 | |
| 2019-12-31 | -$14.00K 10-Q · filed 2021-02-02 | -$30.00K 10-Q · filed 2021-02-02 | ||
| 2019-09-30 | -$16.00K 10-Q · filed 2020-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |